Paclitaxel, Folic Acid, and Lometrexol in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Folic acid may protect normal cells from the side effects of
chemotherapy and may increase the effectiveness of chemotherapy by making tumor cells more
sensitive to the drug. Lometrexol may stop the growth of tumors by blocking one of the
enzymes necessary for cancer cell growth. Combining chemotherapy with folic acid and
lometrexol may kill more tumor cells.
PURPOSE: Phase I trial to study the effectiveness of combining paclitaxel, folic acid, and
lometrexol in treating patients who have locally advanced or metastatic solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Jonsson Comprehensive Cancer Center
Collaborator:
National Cancer Institute (NCI)
Treatments:
Albumin-Bound Paclitaxel Folic Acid Lometrexol Paclitaxel Tetrahydrofolates Vitamin B Complex